Ultragenyx Pharmaceutical stock gains after FDA approval and fresh analyst targets

Published on 09/19/2026 at 20:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ultragenyx Pharmaceutical stock closed at USD 14.51 on September 18, 2026 after jumping 13% on the FDA approval of Fayuvi gene therapy. Citigroup and Morgan Stanley have recently raised their price targets, while consensus now stands at USD 34.42.

RARE, US74930A1043, Illustration mit AI erstellt.

Ultragenyx Pharmaceutical Inc. (ISIN US74930A1043) stock is trading in the mid-teens after a sharp reaction to the recent U.S. FDA approval of its Fayuvi gene therapy, with a closing price of USD 14.51 on Nasdaq as of September 18, 2026 per MarketBeat data.

FDA approval of first Sanfilippo gene therapy drives interest

In September 2026, Ultragenyx secured full U.S. FDA approval for Fayuvi (UX111), branded Fayuvi, as the first-ever treatment for pediatric patients with Sanfilippo syndrome Type A, a rare neurodegenerative disorder in children, and received a Priority Review Voucher as part of the decision, according to Yahoo Finance.

Fayuvi has been priced in the United States at USD 3.95 million per treatment, placing it among the world’s most expensive medicines, as highlighted by TechArcade.

Investors reacted quickly to the approval: Ultragenyx shares rose by about 13% on the day the FDA decision was announced, according to BioSpace figures cited by TechArcade, underscoring the market’s view of the therapy as a major long-term value driver.

Stock performance, valuation and consensus expectations

Ultragenyx Pharmaceutical stock closed at USD 14.51 on Nasdaq on September 18, 2026, up 0.01 dollars or 0.07% from the prior session, with after-hours trading at USD 14.55 on the same date, per data compiled by MarketBeat.

At that price, Ultragenyx carried a market capitalization of about USD 1.43 billion, while the 52-week trading range stood between USD 12.73 and USD 39.89 as of September 18, 2026, according to MarketBeat.

Ultragenyx shares started calendar 2026 around USD 23.00 and have since fallen by 36.9% to USD 14.51 as of September 18, 2026, even after the Fayuvi approval bounce, based on performance data from MarketBeat.

Analyst sentiment is mixed but skewed positive: Ultragenyx Pharmaceutical currently holds a consensus rating of Hold, with an average rating score of 2.48 derived from 1 strong buy, 9 buy, 10 hold and 1 sell recommendation, and a consensus price target of USD 34.42, implying roughly 137.2% upside from the USD 14.51 spot price, according to MarketBeat.

Fresh analyst calls after Fayuvi approval

Several houses have updated their views following recent developments. Citigroup raised its Ultragenyx Pharmaceutical price target from USD 31.00 to USD 32.00 while reiterating a buy rating in a research note released on a recent Friday, according to Ground News.

Morgan Stanley has maintained its Equal-Weight stance on Ultragenyx Pharmaceutical but lifted its price target to USD 20.00 in a recent update, as reported by Futunn News, signaling cautious optimism about the stock’s risk-reward profile.

According to coverage summarized by The Globe and Mail, Canaccord Genuity analyst Whitney Ijem has reiterated a Buy rating on Ultragenyx Pharmaceutical with a price target of USD 39.00, offering one of the higher near-term targets among recent notes.

Despite the broad upside implied by these targets, Ultragenyx currently carries a Zacks Rank of 3, corresponding to Hold, reflecting the balance between promising pipeline assets and execution and funding risks in the rare disease space, as noted by Zacks.

Pipeline, sales potential and risk factors

Looking at fundamentals and outlook, William Blair analyst Sami Corwin has modeled roughly USD 325 million in potential peak sales for Fayuvi, while noting that Ultragenyx faces a relatively thin slate of additional near-term catalysts beyond this approval, according to commentary cited by TechArcade.

On the profitability side, Ultragenyx remains loss-making, with trailing twelve-month earnings per share around negative USD 5.84, according to MarketBeat, underlining that the investment case still hinges on revenue growth from approved therapies and disciplined cost management rather than current profits.

Investors also need to factor in execution risks common to gene therapies, including manufacturing scalability, long-term safety monitoring and payer acceptance for very high list prices. As BowTiedBiotech notes, Fayuvi’s nearly USD 4 million price tag places it under intense scrutiny from health systems and insurers even as it addresses a devastating disease with no prior approved treatment.

RAR E stock level and investor takeaway

Ultragenyx Pharmaceutical stock currently trades well below its 52-week high, with the USD 14.51 Nasdaq close on September 18, 2026 sitting roughly one third of the way up from the 52-week low of USD 12.73 toward the high of USD 39.89, illustrating both the recent pressure on the shares and the substantial upside implied if Fayuvi and other pipeline assets deliver on expectations.